Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluation of Epilepsy Classification and Optimal Treatment Plan in Post-Stroke Epilepsy: A Single Center Experience
Epilepsy/Clinical Neurophysiology (EEG)
P6 - Poster Session 6 (12:00 PM-1:00 PM)

Post-stroke epilepsy (PSE) is a common complication of both ischemic and hemorrhagic stroke. PSE accounts for about 11% of adult epilepsy cases and 45% of epilepsy cases at age of 65 years or older. PSE are thought to be caused by the increase of intracellular Ca2+ and Na+ with a resultant of lower threshold for depolarization, glutamate excitotoxicity, hypoxia, metabolic dysfunction, global hypoperfusion, or hyper-perfusion injury. PSE is a well-known complication in stroke patient; however, the epilepsy classification, seizure activity, and optimal treatment plan remains unknown.

Characterize epilepsy classification in post-stroke epilepsy and defining an optimal treatment regimen for patients with post-stroke epilepsy in a single center experience.

We performed a retrospective review of the electronic medical records at the University of Utah Health and queried charts of patients with a diagnosis of stroke and epilepsy who were also evaluated on at least one occasion by a Neurologist between January 2000 to October 2019.

We identified over 2000 unique patients with possible diagnosis of post-stroke epilepsy. Patients average age are 68.5±18.1 years (range from 19 to 97), with 53% male. We describe their stroke location, epilepsy classification, current anti-epileptic drugs (AEDs), seizure activity, as well as other demographic data, and clinical data.

Over 10% of adult epilepsy cases are caused by PSE. We are performing retrospective chart review on this cohort to provide a detailed characterization of common epilepsy classification in PSE and to decide optimal treatments plans for PSE patients. 
Lilly Fagatele (University of Utah Neurology)
Ms. fagatele has nothing to disclose.
Ka-Ho Wong (U of U Neurology Clinic) The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Cecilia Peterson An immediate family member of Ms. Peterson has received personal compensation for serving as an employee of 100Plus.
No disclosure on file
Amir M. Arain, MD, FAAN (University of Utah) Dr. Arain has nothing to disclose.
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has stock in Certus. Dr. De Havenon has stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
Blake Newman, MD (University of Utah) Dr. Newman has nothing to disclose.